Product logins

Find logins to all Clarivate products below.


Richard Massey

Director, Medical Writing

Richard leads Clarivate’s Value Communication Centre of Excellence and provides strategic guidance for the team of medical writers and creative designers. Having come from a scientific marketing background, Richard brings an astute commercial perspective to the team. Collaborating with clients in the pharmaceutical and medical device industries, Richard has successfully delivered payer value propositions, objection handlers, evidence dossiers, HTA submissions, publications, and training workshops for Top 10 Pharma brands across a comprehensive range of treatment and domain areas. Richard has considerable experience message testing in major markets. He has hosted workshops on value proposition development, objection handling, payer archetypes and HTA trends, and has developed and presented webinars on a variety of market access topics.

Richard has over 10 years of experience in scientific communication roles. Prior to joining Clarivate, Richard was content lead at a Cambridge-based life science marketing agency, creating collateral for global life science brands. His work has featured in leading trade media publications and has been published by Nature, Scientific American and Chemistry World. Richard has a PhD in Organic Chemistry from Durham University.


arrow_forward
Get in touch with Richard

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全